Ann Pediatr Endocrinol Metab.  2018 Jun;23(2):70-74. 10.6065/apem.2018.23.2.70.

Fertility preservation in pediatric and young adult female cancer patients

• Kim H
• Kim H
• Ku SY

• KMID: 2417762
• DOI: http://doi.org/10.6065/apem.2018.23.2.70

Abstract

As the 5-year survival rate increases up to 80% in pediatric cancer patients, the number of women patients with reduced gonadal function by chemotherapy and radiotherapy increases. The gonadal toxicity of pediatric patients varies highly according to the chemotherapeutic agent and the type of radiotherapy. Although American Society of Clinical Oncology published the guideline for fertility preservation, additional scientific and ethical concerns should be considered for clinical practice. In addition, only the experimental method can be applied for the prepubertal patients in contrast to the postpubertal patients. In this review, we will discuss some options for preserving fertility among women's quality of life issues.

Keyword

Fertility preservation; Pediatric cancer; Female infertility

MeSH Terms

Drug Therapy
Female*
Fertility Preservation*
Fertility*
Gonads
Humans
Infertility, Female
Medical Oncology
Methods
Quality of Life
Radiotherapy
Survival Rate
Young Adult*

Reference

References

1. CureSearch. Childhood cancer statics [Internet]. Bethesda (MD): CureSearch;[cited 2018 Mar 1]. Available from: https://curesearch.org/Childhood-Cancer-Statistics.

2. Ministry of Health & Welfare, National Cancer Center, Korea Central Cancer Registry. Annual report of cancer statistics in Korea in 2015. Goyang (Korea): National Cancer Center;2017.

3. National Cancer Institute. Cancer in children and adolescents [Internet]. Bethesda (MD): National Cancer Institute;[cited 2018 Mar 1]. Available from: http://www.cancer.gov/types/childhood-cancers/child-adolescentcancers-fact-sheet.

4. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013; 31:2500–10.

5. Practice Committee of American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2013; 100:1214–23.

6. Adams E, Hill E, Watson E. Fertility preservation in cancer sur vivors: a national sur vey of oncologists' current knowledge, practice and attitudes. Br J Cancer. 2013; 108:1602–15.

7. Forman EJ, Anders CK, Behera MA. A nationwide survey of oncologists regarding treatment-related infertility and fertility preservation in female cancer patients. Fertil Steril. 2010; 94:1652–6.

8. Yee S, Fuller-Thomson E, Lau A, Greenblatt EM. Fertility preservation practices among Ontario oncologists. J Cancer Educ. 2012; 27:362–8.

9. Ethics Committee of American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. Fertil Steril. 2013; 100:1224–31.

10. Lee S, Ozkavukcu S, Heytens E, Moy F, Oktay K. Value of early referral to fertility preservation in young women with breast cancer. J Clin Oncol. 2010; 28:4683–6.

11. Kim J, Mersereau JE. Early referral makes the decisionmaking about fertility preservation easier: a pilot survey study of young female cancer survivors. Support Care Cancer. 2015; 23:1663–7.

12. Chemaitilly W, Mertens AC, Mitby P, Whitton J, Stovall M, Yasui Y, et al. Acute ovarian failure in the childhood cancer survivor study. J Clin Endocrinol Metab. 2006; 91:1723–8.

13. Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol. 2016; 12:2333–44.

14. Green DM, Nolan VG, Goodman PJ, Whitton JA, Srivastava D, Leisenring WM, et al. The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer. 2014; 61:53–67.

15. Meirow D. Reproduction post-chemotherapy in young cancer patients. Mol Cell Endocrinol. 2000; 169:123–31.

16. Bakker B, Oostdijk W, Bresters D, Walenkamp MJ, Vossen JM, Wit JM. Disturbances of growth and endocrine function after busulphan-based conditioning for haematopoietic stem cell transplantation during infancy and childhood. Bone Marrow Transplant. 2004; 33:1049–56.

17. Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod. 2003; 18:117–21.

18. Rodriguez-Wallberg KA, Oktay K. Fertility preservation during cancer treatment: clinical guidelines. Cancer Manag Res. 2014; 6:105–17.

19. Wallace WH, Thomson AB, Saran F, Kelsey TW. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys. 2005; 62:738–44.

20. Brougham MF, Wallace WH. Subfertility in children and young people treated for solid and haematological malignancies. Br J Haematol. 2005; 131:143–55.

21. De Bruin ML, Van Dulmen-den Broeder E, Van den Berg MH, Lambalk CB. Fertility in female childhood cancer survivors. Endocr Dev. 2009; 15:135–58.

22. Jadoul P, Dolmans MM, Donnez J. Fertility preservation in girls during childhood: is it feasible, efficient and safe and to whom should it be proposed? Hum Reprod Update. 2010; 16:617–30.

23. Salama M, Isachenko V, Isachenko E, Rahimi G, Mallmann P. Updates in preserving reproductive potential of prepubertal girls with cancer: systematic review. Crit Rev Oncol Hematol. 2016; 103:10–21.

24. Burns KC, Hoefgen H, Strine A, Dasgupta R. Fertility preservation options in pediatric and adolescent patients with cancer. Cancer. 2018; 124:1867–76.

25. Borini A, Lagalla C, Bonu MA, Bianchi V, Flamigni C, Coticchio G. Cumulative pregnancy rates resulting from the use of fresh and frozen oocytes: 7 years' experience. Reprod Biomed Online. 2006; 12:481–6.

26. Grifo JA, Noyes N. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients. Fertil Steril. 2010; 93:391–6.

27. Kim TJ, Laufer LR, Hong SW. Vitrification of oocytes produces high pregnancy rates when carried out in fertile women. Fertil Steril. 2010; 93:467–74.

28. Noyes N, Porcu E, Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online. 2009; 18:769–76.

29. Pacheco F, Oktay K. Current success and efficiency of autologous ovarian transplantation: a meta-analysis. Reprod Sci. 2017; 24:1111–20.

30. Demeestere I, Simon P, Dedeken L, Moffa F, Tsépélidis S, Brachet C, et al. Live birth after autograft of ovarian tissue cryopreserved during childhood. Hum Reprod. 2015; 30:2107–9.

31. Walsh F. Woman has baby using ovary frozen in childhood. BBC News [Internet]. 2016. Dec. 14. [cited 2018 Mar 1]; Health [about 3 p]. Available from: http://www.bbc.com/news/health-38312995.

32. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist. 2007; 12:1044–54.

33. Oktay K, Rodriguez-Wallberg K, Munster P. Ovarian protection during adjuvant chemotherapy. N Engl J Med. 2015; 372:2268–9.

34. Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA. 2015; 314:2632–40.

35. Del Mastro L, Ceppi M, Poggio F, Bighin C, Peccatori F, Demeestere I, et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev. 2014; 40:675–83.

36. Munhoz RR, Pereira AA, Sasse AD, Hoff PM, Traina TA, Hudis CA, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2016; 2:65–73.

37. Elgindy E, Sibai H, Abdelghani A, Mostafa M. Protecting ovaries during chemotherapy through gonad suppression: a systematic review and meta-analysis. Obstet Gynecol. 2015; 126:187–95.

38. Chen H, Li J, Cui T, Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev. 2011; (11):CD008018.

39. Winkler-Crepaz K, Ayuandari S, Ziehr SC, Hofer S, Wildt L. Fertility preservation in cancer survivors. Minerva Endocrinol. 2015; 40:105–18.